title: Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.
abstract: OBJECTIVE
  The cell adhesion molecule integrin α(v)β(3) is an important player in the process of tumor angiogenesis and metastasis. Abegrin™, a fully humanized anti-integrin α(v)β(3) monoclonal antibody, was currently in clinical trials for cancer therapy. Herein, we labeled Abegrin™ with (111)In, evaluated the in vitro and in vivo characteristics, and investigated whether the expression of integrin α(v)β(3) in tumors could be imaged with (111)In-labeled Abegrin™.
  
  
  METHODS
  The binding affinity and specificity of Abegrin™ was analyzed using U87MG glioblastoma cells. Abegrin™ was coupled with 1,4,7,10-tetraazadodecane-N,N',N",N'″-tetraacetic acid (DOTA) for (111)In radiolabeling. γ Imaging of (111)In-DOTA-Abegrin™ was carried out in nude mice bearing both integrin α(v)β(3)-positive U87MG and integrin α(v)β(3)-negative HT-29 tumors. Biodistribution and blocking studies of (111)In-DOTA-Abegrin™ were investigated in U87MG tumor-bearing nude mice.
  
  
  RESULTS
  Abegrin™ exhibited high-binding affinity to human integrin α(v)β(3) expressed on U87MG cells (K (d) of 0.35 ± 0.06 nM). The antibody retained antigen-binding affinity/specificity after DOTA conjugation. γ Imaging showed that the tumor uptake of (111)In-DOTA-Abegrin™ in integrin α(v)β(3)-positive U87MG tumors was much higher than that in integrin α(v)β(3)-negative HT-29 tumors. In the HT-29 tumors, Abegrin™ was mainly nonspecifically accumulated around the blood vessels, while in the U87MG tumors, besides the nonspecific tumor retention, Abegrin™ also specifically bound the human integrin α(v)β(3) expressed on the tumor cells. Biodistribution and blocking studies exhibited that the U87MG tumor uptake of (111)In-DOTA-Abegrin™ decreased from 14.12 ± 0.44 to 6.93 ± 0.94 percentage of injected dose per gram of tissue after coinjection of excess dose of cold Abegrin™, which confirmed the in vivo integrin α(v)β(3) binding specificity of (111)In-DOTA-Abegrin™.
  
  
  CONCLUSIONS
  Abegrin™ showed specific binding to human integrin α(v)β(3) expressed on the tumor cells. (111)In-DOTA-Abegrin™ can specifically target the human integrin α(v)β(3) expression in the nude mouse model. (111)In-DOTA-Abegrin™ has a potential for clinical translation as an agent for integrin α(v)β(3)-positive tumor imaging, evaluating tumor angiogenic status and monitoring the therapeutic efficacy of Abegrin™-based cancer therapy.
authors.affiliation: Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.
authors.forename: Zhaofei
authors.initials: Z
authors.lastname: Liu
authors.forename: Bing
authors.initials: B
authors.lastname: Jia
authors.forename: Huiyun
authors.initials: H
authors.lastname: Zhao
authors.forename: Xiaoyuan
authors.initials: X
authors.lastname: Chen
authors.forename: Fan
authors.initials: F
authors.lastname: Wang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D045744:Cell Line, Tumor; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007205:Indium Radioisotopes / Q000378:metabolism* / Q000493:pharmacokinetics; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D023421:Models, Animal; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007205:Indium Radioisotopes; D039302:Integrin alphaVbeta3; C112567:etaracizumab
references.citation: Bioconjug Chem. 2008 Jun;19(6):1170-8
references.pmid: 18491928
references.citation: Cancer Res. 2006 Oct 1;66(19):9673-81
references.pmid: 17018625
references.citation: Cancer Biother Radiopharm. 2001 Apr;16(2):125-32
references.pmid: 11385959
references.citation: J Nucl Med. 2009 Jul;50(7):1168-77
references.pmid: 19525469
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8674-82
references.pmid: 15623652
references.citation: Curr Oncol Rep. 2006 Mar;8(2):96-103
references.pmid: 16507218
references.citation: J Nucl Med. 2008 Nov;49(11):1809-12
references.pmid: 18927323
references.citation: N Engl J Med. 2001 Sep 27;345(13):995-6
references.pmid: 11575295
references.citation: Clin Cancer Res. 2008 Nov 15;14(22):7330-9
references.pmid: 19010848
references.citation: J Nucl Med. 2006 May;47(5):763-9
references.pmid: 16644745
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6
references.pmid: 18006761
references.citation: Drug Dev Res. 2008;69(6):329-339
references.pmid: 20628538
references.citation: J Nucl Med. 2009 Jan;50(1):123-31
references.pmid: 19091906
references.citation: Curr Drug Targets. 2003 Feb;4(2):123-31
references.pmid: 12558065
references.citation: Invest New Drugs. 2008 Feb;26(1):35-43
references.pmid: 17876527
references.citation: Proc Natl Acad Sci U S A. 1998 May 26;95(11):6037-42
references.pmid: 9600913
references.citation: Int Immunopharmacol. 2003 Mar;3(3):319-28
references.pmid: 12639809
references.citation: J Clin Invest. 1999 May;103(9):1227-30
references.pmid: 10225964
references.citation: J Nucl Med. 2009 Jan;50(1):116-22
references.pmid: 19091899
references.citation: Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):81-93
references.pmid: 18712381
references.citation: Science. 1999 Aug 13;285(5430):1028-32
references.pmid: 10446041
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1557-61
references.pmid: 1371877
references.citation: Curr Cancer Drug Targets. 2006 Mar;6(2):89-105
references.pmid: 16529540
references.citation: J Med Chem. 2009 Jan 22;52(2):425-32
references.pmid: 19113865
references.citation: Biochem Biophys Res Commun. 2006 Oct 20;349(2):816-24
references.pmid: 16950201
references.citation: Clin Cancer Res. 2000 Aug;6(8):3056-61
references.pmid: 10955784
references.citation: Eur J Cancer. 2008 Sep;44(13):1835-40
references.pmid: 18632262
references.citation: Science. 1994 Apr 22;264(5158):569-71
references.pmid: 7512751
references.citation: Adv Enzyme Regul. 2001;41:189-207
references.pmid: 11384745
references.citation: Cancer Biother Radiopharm. 2009 Feb;24(1):15-24
references.pmid: 19216631
references.citation: Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):947-57
references.pmid: 19159928
references.citation: Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12462-7
references.pmid: 17626788
references.citation: Cancer Res. 2008 Dec 1;68(23):9746-53
references.pmid: 19047153
references.citation: J Nucl Med. 2008 Jul;49(7):1066-74
references.pmid: 18552139
references.citation: Cell. 1992 Apr 3;69(1):11-25
references.pmid: 1555235
references.citation: Anticancer Agents Med Chem. 2006 Sep;6(5):407-28
references.pmid: 17017851
references.citation: Neuroreport. 2008 Jul 2;19(10):1009-14
references.pmid: 18580570
references.citation: J Med Chem. 2004 Mar 11;47(6):1465-74
references.pmid: 14998334
references.citation: J Neuropathol Exp Neurol. 1996 Nov;55(11):1143-9
references.pmid: 8939197